Fadi Asfour
No Rating Available
(Learn About Our Rating System)

Fadi Asfour, MD, MBBS

Languages spoken: English, Arabic

Clinical Locations

Eccles Primary Children's Outpatient Services

Salt Lake City
801-213-3599

  • Dr. Asfour received his Bachelor of Medicine, Bachelor of Surgery degree from Jordan University of Science and Technology. Dr. Asfour completed his pediatric residency at the Women and Children´s Hospital of Buffalo, and his pediatric Pulmonary Fellowship at Children’s Hospital of Los Angeles. Dr. Asfour is board-certified in pediatric pulmonology.


    Dr. Asfour is currently a Professor in the Department of Pediatrics at the University of Utah and is in the Division of Pulmonary and Sleep Medicine at Primary Children´s Hospital. Dr. Asfour’s clinical interests include cystic fibrosis, quality improvement, patient experience, team well-being, and global access to care. Dr. Asfour currently serves as the medical director of quality improvement at Primary Children’s Hospital. In November of 2022, Dr. Asfour was named the inaugural holder of the Barbara Chatfield Endowed Chair for cystic fibrosis in the University of Utah.

    Specialties

    Board Certification

    American Board of Pediatrics (Sub: Pediatric Pulmonology)
    National Board of Medical Examiners

  • Dr. Asfour received his Bachelor of Medicine, Bachelor of Surgery degree from Jordan University of Science and Technology. Dr. Asfour completed his pediatric residency at the Women and Children´s Hospital of Buffalo, and his pediatric Pulmonary Fellowship at Children’s Hospital of Los Angeles. Dr. Asfour is board-certified in pediatric pulmonology.


    Dr. Asfour is currently a Professor in the Department of Pediatrics at the University of Utah and is in the Division of Pulmonary and Sleep Medicine at Primary Children´s Hospital. Dr. Asfour’s clinical interests include cystic fibrosis, quality improvement, patient experience, team well-being, and global access to care. Dr. Asfour currently serves as the medical director of quality improvement at Primary Children’s Hospital. In November of 2022, Dr. Asfour was named the inaugural holder of the Barbara Chatfield Endowed Chair for cystic fibrosis in the University of Utah.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Primary
    Board Certification
    American Board of Pediatrics (Sub: Pediatric Pulmonology)
    National Board of Medical Examiners

    Education history

    Fellowship Pulmonary - University of Southern California at Children’s Hospital Los Angeles Fellow
    Residency Pediatric - University of Buffalo at The Women and Children’s Hospital of Buffalo M.D.
    Internship Internal Medicine/Preliminary - North Side Hospital, Affiliated with North Eastern Ohio Universities Colleges of Medicine Intern
    Internship Al-Basheer Hospital Intern
    Professional Medical Medicine - Jordan University of Science and Technology/King Abdullah University Hospital M.B.B.S.

    Selected Publications

    Journal Article

    1. Cathy Liu, Taiya R Bach, Philip M Farrell, Derek Pavelec, Nicholas J Antos, Michael J Rock, Fadi Asfour, Michelle Howenstine, Jonathan M Gaffin, HuiChuan J Lai (2024). Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis. J Pediatr Gastroenterol Nutr, (2024), 1-10.
    2. Gamel B, Albon D, Bandla S, Davison DW, Flath J, Sabadosa KA, Seid M, Silva L, Ong T, Cystic Fibrosis Learning Network Group (2024). Interventions to improve system-level coproduction in the Cystic Fibrosis Learning Network. BMJ Open Qual, 13(3). (Read full article)
    3. Blaseg NA, Robson JO, Patel RA, Asfour F, Pohl JF (2024). Gastrointestinal Pathologies in Pediatric Patients With Cystic Fibrosis Undergoing Endoscopy: A Single-Center Retrospective Review Over 15 Years. Cureus, 16(4), e59018. (Read full article)
    4. Reed JE, Johnson JK, Zanni R, Messier R, Asfour F, Godfrey MM (2024). Quality of locally designed surveys in a quality improvement collaborative: review of survey validity and identification of common errors. BMJ Open Qual, 13(1). (Read full article)
    5. Liou TG, Argel N, Asfour F, Brown PS, Chatfield BA, Cox DR, Daines CL, Durham D, Francis JA, Glover B, Helms M, Heynekamp T, Hoidal JR, Jensen JL, Kartsonaki C, Keogh R, Kopecky CM, Lechtzin N, Li Y, Lysinger J, Molina O, Nakamura C, Packer KA, Paine R 3rd, Poch KR, Quittner AL, Radford P, Redway AJ, Sagel SD, Szczesniak RD, Sprandel S, Taylor-Cousar JL, Vroom JB, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN, Adler FR (2024). Airway inflammation accelerates pulmonary exacerbations in cystic fibrosis. iScience, 27(3), 108835. (Read full article)
    6. Yuzyuk T, McDonald CM, Zuromski LM, De Biase I, Johnson L, Williams N, Meihls S, Asfour F (2023). Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy. J Cyst Fibros. (Read full article)
    7. Zobell JT, Moss J, Creelman J, Christensen R, Jensen B, Stewart J, Ameel K, Asfour F (2023). Implementation of a comprehensive pharmacy-driven immunization care process model in a pediatric cystic fibrosis clinic. Pediatr Pulmonol. (Read full article)
    8. Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA, VX16-809-122 Study Group (2022). A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age With Cystic Fibrosis Homozygous for F508del-CFTR. Am J Respir Crit Care Med. (Read full article)
    9. Huang L, Lai HJ, Antos N, Rock MJ, Asfour F, Howenstine M, Gaffin JM, Farrell PM (2022). Defining and identifying early-onset lung disease in cystic fibrosis with cumulative clinical characteristics. Pediatr Pulmonol. (Read full article)
    10. Albon D, Thomas L, Hoberg L, Stamper S, Somerville L, Varghese P, Balasa E, Roman M, Britto MT, Miner M, Gehring E, Gammon C, Amin RS, Seid M, Powers M, CF Learning Network telehealth iLab working group (2022). Cystic fibrosis learning network telehealth innovation lab during the COVID-19 pandemic: a success QI story for interdisciplinary care and agenda setting. BMJ Open Qual, 11(2). (Read full article)
    11. David P Nichols, Pradeep K Singh, Arthur Baines, Lindsay J Caverly, James F Chmiel, Ronald L GIbson, Jorge Lascano, Sarah J Morgan, George Retsch- Bogart, Lisa Saiman, Hossein Sadeghi, Joanne L Billings, Sonya L Heltshe, Shannon Kirby, Ada Kong, Jerry A Nick, Nicole Mayer- Hamblett, TEACH Study Group (2021). Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax.

    Abstract

    1. Yuzyuk, T Balogun, K Meihls, S Williams, N McDonald, KM Asfour, F (2020). Dyslipidemia in Children and Adolescents with Cystic Fibrosis [Abstract]. 55(S2).